



Human Papillomavirus (HPV) Vaccination Report: Nevada

Working Together to Reach National Goals for HPV Vaccination


December 2016

This quarter's Human Papillomavirus (HPV) Vaccination Report focuses on the **recent Advisory Committee on Immunization Practices (ACIP) recommendation for use of a 2-dose schedule for HPV vaccination**. Adolescents who receive their first dose of HPV vaccine before their 15th birthday will now only need two doses, given 6 to 12 months apart. However, three vaccine doses continue to be recommended for those initiating the series on or after the 15th birthday, and for those with certain immunocompromising medical conditions. This recommendation followed the U.S. Food and Drug Administration's (FDA) approval of Gardasil 9 (9-valent HPV vaccine) for use in a 2-dose series for adolescents aged 9 through 14 years. See page 2 of this report for more guidance on the 2-dose recommendation, as well as new HPV vaccination resources and materials.

2016 HPV Vaccine Distribution Trends in Nevada

Below are available year-to-date totals of CDC and non-CDC distributed HPV vaccine doses of Gardasil (quadrivalent HPV vaccine) and 9-valent HPV vaccine in your state or city. Please note that as of **October 25th, quadrivalent HPV vaccine is no longer available for order in the United States**. CDC recommends examining vaccine distribution data for trends to approximate recent HPV vaccine administration.

Year-to-date Total of Distributed[†] Quadrivalent HPV Vaccine and 9-Valent HPV Vaccine Doses in Nevada (2012-2016)



Year-to-Date Total of Distributed[†] Quadrivalent and 9-Valent HPV Vaccine, NV (2015-2016)

	2015	2016	% change
Jan	4,318	6,062	40.4%
Feb	10,420	12,107	16.2%
Mar	16,071	18,969	18.0%
Apr	19,812	25,709	29.8%
May	29,218	31,211	6.8%
Jun	35,377	38,384	8.5%
Jul	47,711	51,846	8.7%
Aug	60,473	66,073	9.3%
Sept	69,157	75,835	9.7%
Oct	75,578		
Nov	82,573		
Dec	89,229		

[†]These data represent an estimate of all Gardasil and Gardasil 9 HPV vaccine doses distributed in Nevada.

Note: Cervarix doses, which represent less than 1% of the HPV vaccine doses distributed in the United States, are not included in this report.

Have questions? Contact us at preteenvaccines@cdc.gov.





Human Papillomavirus (HPV) Vaccination Report: Nevada

Working Together to Reach National Goals for HPV Vaccination

December 2016

Summary: ACIP Recommendations for HPV Vaccination

HPV vaccines are highly effective and safe, and are powerful prevention tools for reducing the burden of vaccine-preventable HPV-associated infections and cancers.[†] Although the number of doses recommended for some age groups has changed, HPV remains a routinely recommended vaccine for adolescents aged 11–12 years.[‡] It is also recommended that adolescents aged 11–12 years receive vaccines against tetanus, diphtheria, and pertussis (Tdap), and bacterial meningitis (MenACWY); all three vaccines (Tdap, HPV, and MenACWY) should be administered during the same visit. The recent 2-dose recommendation provides an opportunity to achieve protection against vaccine-preventable HPV-associated cancers with two office visits instead of three. This recommendation also gives parents extra incentive to protect their children on time at ages 11–12 years, as teens are recommended to get three doses if they wait until their 15th birthday or thereafter to initiate the vaccine series.

[†]Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination — Updated Recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep* 2016; 65:1405–1408. DOI: <http://dx.doi.org/10.15585/mmwr.mm6549a5>

[‡]Vaccination series can be started at 9 years of age

Recommended Number of Doses and Intervals for HPV Vaccine by Age at Series Initiation and Medical Conditions, United States 2016

Population(s)	Recommended number of HPV vaccine doses	Recommended interval between doses
Persons initiating HPV vaccination at ages 9 through 14 years, except immunocompromised persons [†]	2	0, 6–12 months [§]
Persons initiating HPV vaccination at ages 15 through 26 years	3	0, 1–2, 6 months ^{**}
Immunocompromised persons [†] initiating HPV vaccination at ages 9 through 26 years	3	0, 1–2, 6 months ^{**}

[†]Persons with primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral immunity

[§]In a 2-dose HPV vaccination schedule, the minimum interval between the first and second doses is 5 months.

^{**}In a 3-dose schedule of HPV vaccine, the minimum intervals between doses are:

- 4 weeks between the first and second dose,
- 12 weeks between the second and third dose, and
- 5 months between the first and third dose.

Additional HPV Vaccination Information and Resources

- CDC’s **MMWR policy note** contains more information on the recent ACIP recommendations: https://www.cdc.gov/mmwr/volumes/65/wr/mm6549a5.htm?s_cid=mm6549a5_e
- **Current Issues in Immunization NetConference.** Lauri E Markowitz, MD - CDC’s Associate Director of Science for HPV, reviews the updated HPV vaccination recommendations: <http://www.cdc.gov/vaccines/ed/ciinc/2016-10-26.html>.
- **Clinician FAQ: CDC Recommendations for HPV Vaccine 2-Dose Schedules** explains the reasons for changing the HPV vaccine recommendation and provides tips for talking with parents about the change: <http://www.cdc.gov/hpv/downloads/hcvg15-ptt-hpv-2dose.pdf>.
- **Package insert for 9-valent HPV vaccine**, updated after FDA approval for use in a 2-dose series for adolescents aged 9 through 14 years: <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm426445.htm>.
- Access CDC’s **“tip sheet”** for guidance on answering questions parents may have about the HPV vaccine: <https://www.cdc.gov/vaccines/who/teens/for-hcp-tipsheet-hpv.pdf>.
- **CDC’s HPV Toolkit** is designed to help partners and programs increase HPV vaccination rates: <http://www.cdc.gov/hpv/partners/index.html>.

Have questions? Contact us at preteenvaccines@cdc.gov.

